RETpositive/ LUNGevity Award

The 2024 RETpositive/LUNGevity Translational Research Award Program for RET-positive Cancer program is now open for application submissions.

The 2024 RETpositive/LUNGevity Translational Research Award Program for RET-positive Cancer is expected to have a direct impact on the outcomes of patients with advanced RET-positive cancer, but innovative proposals that address other unmet needs in the RET-positive cancer space are also invited for submission. In keeping with the mission of the RETpositive group, proposals focusing on multiple types of RET-positive cancers or with a clear impact on multiple types of RET-positive cancers will be given priority. This RFA will NOT address proposals related to psychosocial research. The program has no geographical restrictions and is open to both US and non-US applicants.

Award Guidelines

• Applicants must hold a doctoral degree and faculty appointment (or equivalent) with an academic institution, including research institutions that are not formally associated with a university, and have completed a postdoctoral training fellowship.
• Awards may be for a maximum of $100,000 ($50,000 per year for 2 years)
• Annual milestones must be met

Note: LUNGevity will grant only one award per institution.

LUNGevity uses a two-step application process:

1. A letter of intent (LOI), with a brief overview of the proposed project and biographical information
2. A full application with an extended narrative about the project, as well as supporting information and documentation. (Because the number of awards is limited, only a subset of applicants will be invited to submit a full application after the LOI review is completed.)

Reviewers are drawn from LUNGevity's Scientific Advisory Board and other lung cancer experts. Awardees have progress and financial reporting obligations during their award term.

A complete description of the award, terms and conditions, and instructions are included in the 2024 RETpositive/LUNGevity Translational Research Award Program for RET-positive Cancer RFA. All application materials must be submitted electronically via proposalCENTRAL.

2024 Award Timeline